XVir Therapeutics
Pre-clinicalXVir® Therapeutics GmbH is a biopharmaceutical company, which provides YB-1 dependent oncolytic adenoviruses for oncolytic immunotherapy based on selective lysis of tumor cells and concomitant systemic anti-cancer immune response.
Founded
2019
Focus
Viral Technology
About
XVir® Therapeutics GmbH is a biopharmaceutical company, which provides YB-1 dependent oncolytic adenoviruses for oncolytic immunotherapy based on selective lysis of tumor cells and concomitant systemic anti-cancer immune response.
Company Info
TypePrivate
Founded2019
LocationMunich, Germany
StagePre-clinical
Contact
SIMILAR COMPANIES
300Microns
Pre-clinical · Munich
BetaSense
Pre-clinical · Berlin
AB Diagnostic Systems
Pre-clinical · Jena
bbi-biotech
Pre-clinical · Berlin
Mireca Medicines
Pre-clinical · Munich
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile